MacroGenics Inc

NASDAQ:MGNXUnited States

Oct 22, 2024

Show headlines and story abstract

• MacroGenics Signs Deal With TerSera Therapeutics for Sale of Margenza, from 9:39AM ET on Tuesday Oct 22, 2024 by MT Newswires

  9:39AM ET on Tuesday Oct 22, 2024 by MT Newswires
  Companies Mentioned: MGNX
  09:39 AM EDT, 10/22/2024 (MT Newswires) -- MacroGenics (MGNX) and TerSera Therapeutics said Tuesday they have signed an agreement under which TerSera will buy global rights to breast cancer drug Margenza. Under the deal, TerSera will pay MacroGenics...

• DJ MacroGenics to Sell Margenza Cancer Drug for $40 Million, from 7:53AM ET on Tuesday Oct 22, 2024 by Dow Jones

  7:53AM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: MGNX
  
  By Colin Kellaher
  
  MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera Therapeutics for an initial $40 million.
  

• MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA(R), from 7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones

  7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: MGNX
  
  Any statements in this press release about future expectations, plans and prospects for MacroGenics ("Company"), including statements about the Company's strategy, future operations, clinical development of and regulatory plans for the Company's therapeutic candidates, expected timing of the release of final safety and efficacy data, including mature median rPFS and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "potential," "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate's revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate's market acceptance, competition, reimbursement and regulatory actions; future data updates, especially timing and results of mature median radiographic progression-free survival, other efficacy and safety data with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.